0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-77.62%PremiumDec 20, 2024Expiry Date8.67Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.29Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet